doctor head
 
  pharmacy and drugs  
search Search
 
       About us       News      A-Z Drugs      Stores      Top Drugs      Contact  
  doctor doctor hand
 
  doctor legs  
 
 
 
 

  Diseases

  Newsletter
Subscribe to our newsletter:
Name:
E-mail:
    Search results
Search results for: contraindications

1 - 5 of 6 <<previous | next>>

Drugs results:

Atorvastatin

Atorvastatin

Atorvastatin belong to a class of drug known as HMG CoA reductase inhibitor. This drug works by blocking the production of cholesterol (a type of fat) in the body. Indications: to reduce the amounts of low density lipoprotein or LDL (bad) cholesterol, more...

Perindopril tablets

Perindopril

Perindopril is in a class of drugs called angiotensin-converting-enzyme inhibitors (ACE inhibitors). Indications : essential hypertension (to lower high blood pressure), congestive heart failure or CHF ( to decrease the heart’s workload), prevention of st more...

Isotretinoin

Isotretinoin

Isotretinoin is a form of vitamin A which works by decreasing the rate of sebum (oil) production by the sebaceous or oil glands hence, it is used to treat severe forms of acne such as nodular and cystic acne & acne conglobata that has not responded to ant more...

Mupirocin topical

Mupirocin topical

Mupirocin is a topical antibiotic. This medicine prevents bacteria from growing on your skin or used to treat infections of the skin such as impetigo (streptococcal infection) or secondarily infected traumatic lesions e.g. small lacerations, sutured woun more...

Pemetrexed

Pemetrexed

Pemetrexed is used in the treatment of pleural mesothelioma, a form of lung cancer associated with exposure to asbestos. Pemetrexed has a greater effect on rapidly-dividing cells like the cancer cells. It works by interfering the production and maintenan more...

Diseases results:

Reduce cholesterol
High blood pressure
Skin diseases
Bacterial infection
Lung cancer
Onychomycosis

Articles results:

Meeting Highlights From The Committee For Medicinal Products For Human Use (CHMP), 22-24 January 2007
Initial marketing authorisation applicationsThe Committee for Medicinal Products for Human Use (CHMP) gave positive opinions recommending the granting of marketing authorisations for Januvia (sitagliptin) and Xelevia (sitagliptin), from Merck Sharp & Dohme. Both products are intended for the treatment of type-II diabetes mellitus in combination with either metformin or, in certain patients, a PPARg agonist (i.e.


Meeting Highlights From The Committee For Medicinal Products For Human Use, 19-22 March 2007, Europe
Positive opinion for Revlimid The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Revlimid (lenalidomide), from Celgene Europe, for the treatment of multiple myeloma. EMEA review began on 29 March 2006, with an active review time of 199 days. The active substance of Revlimid, lenalidomide, has a chemical structure that resembles that of thalidomide.


Meeting Highlights From The Committee For Medicinal Products For Human Use, 23-26 April 2007, Europe
First accelerated assessment concludedThe European Medicines Agency's (EMEA) Committee for Medicinal Productsfor Human Use (CHMP) has adopted a positive opinion recommending thegranting of a marketing authorisation for the first medicinal productfor human use that has been evaluated by the new accelerated assessmentprocedure.


EMEA CMPH Use Adopts 5 Positive Opinions Recommending The Granting Of A Marketing Authorisation For The Following Medicinal Products
-- Aerinaze (desloratadine 2.5 mg/pseudoephedrine sulphate 120 mg), from Schering-Plough Europe, for the symptomatic treatment of seasonal allergic rhinitis, accompanied by nasal congestion. EMEA review began on 26 July 2006 with an active review time of 196 days.


Meeting Highlights From The Committee For Medicinal Products For Human Use, 18-21 June 2007, Europe Positive Opinions
The European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) has adopted eleven positive opinions, three of which relate to similar biological medicinal products, recommending the granting of a marketing authorisation for the following medicinal products: * Atriance (nelarabine), from Glaxo Group Limited, for the treatment of T-cell acute lymphoblastic leukaemia (T-ALL) and T-cell lymphoblastic leukaemia (T-LBL) of patients in second relapse.




1 - 5 of 6 <<previous | next>>

© 2006-2010 pharmacy-and-drugs.com. All rights reserved.